Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a ...

Teva Pharmaceutical Industries Limited TEVA announced that it has submitted a new drug application (NDA) to the FDA seeking approval for olanzapine, a long-acting subcutaneous injectable (LAI) for ...

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population 2 Olanzapine LAI is designed ...

A 33-year-old woman hears brutal and frightening voices daily but continues her college studies. A middle-aged man, who served in the Navy and has since struggled with substance abuse, spends 10 weeks ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) shares began Tuesday sharply higher. The company today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug ...

For decades, scientists thought that schizophrenia was caused by excessive levels of a neurotransmitter called dopamine, but new research suggests that “a disturbance in dopamine levels” is only “part ...

In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...

Schizophrenia has long been framed as a disorder of broken thoughts and fractured perception, but a new line of research ...

Caplyta (lumateperone) is a prescription drug used to treat schizophrenia in adults. It does not come as a generic drug. Caplyta comes as an oral capsule. The active ingredient in Caplyta is ...

Dr Carney drives a discussion surrounding optimal treatment strategies for schizophrenia. John J. Miller, MD: Dr [Caroline] Carney, which factors do you consider when working with a patient to select ...

Researchers discovered that some variants of the gene known as GRIN2A can cause certain conditions all on their own.